High-Dose CBN: What a Japanese User Survey Reveals

How much cannabinol are people actually taking, and how closely does that resemble the amounts researchers have studied? For a cannabis ingredient increasingly associated with sleep, answering those questions could help turn consumer interest into more useful evidence.

A new Japanese survey, J-NEC2025, examines reported doses, experiences, and reasons for using CBN food products.¹ Accepted by Emerging Trends in Drugs, Addictions, and Health, the paper describes substantial consumption alongside high satisfaction among current users. It also identifies important uncertainties about product composition, adverse effects, and repeated use.

The opportunity is to connect these observations with better experiments. Knowing what consumers take can help researchers design studies that answer practical questions about benefits, appropriate formulations, and next-day functioning.

Why CBN Dose Matters for Sleep Research

Cannabinol, usually shortened to CBN, forms as THC oxidizes. It interacts with CB1 receptors, part of the body’s cannabinoid signaling system, although its activity differs from THC’s. Describing it as a milder cannabinoid does not establish that every quantity produces mild effects.

Dose is only one part of the question. A single supervised administration, repeated consumption at home, and a combination product containing several active ingredients represent different exposures. Evidence from one cannot automatically answer questions about the others.

Recent research gives scientists something concrete to investigate. A 2026 placebo-controlled CBN insomnia trial tested 30 mg and 300 mg in 20 adults. Neither dose significantly improved the primary outcome, time spent awake after initially falling asleep. However, 300 mg improved some secondary measures, including time to fall asleep and subjective sleep quality.

That pattern supports further investigation, with a more precise question than whether CBN simply “works for sleep.” Falling asleep, staying asleep, and functioning well the following morning are distinct outcomes.

How the Japanese CBN Survey Worked

Researchers partnered with seven companies selling CBN food products. Invitations accompanied purchases, and anonymous online responses were collected between October and December 2025. The final analysis included 107 respondents who had used an eligible product within the previous 30 days.

The study covered 15 products, including baked goods, gummies, oils, a capsule, and a powder. No respondent reported using the powder. Participants described how much they initially consumed and what amount they currently considered appropriate.

Researchers estimated CBN quantities by multiplying reported portions by manufacturers’ declared contents. These were label-based estimates, not measurements of what entered participants’ bloodstreams. Some people reported multiple products, producing 131 first-use records from the 107 respondents.

This distinction matters: the study describes exposure across reported product uses, rather than assigning one simple average dose to every participant.

What the CBN Edibles Study Found

Estimated first-use intake averaged 198.7 mg per occasion across those records. The amount respondents currently considered appropriate averaged 251.5 mg across 129 records. The second figure describes a judgment, not verified ongoing consumption.

Health concerns motivated much of the use. Eighty respondents, or 74.8%, reported health-related purposes, sometimes alongside recreation. Among those 80 people, 65% identified insomnia or sleep problems as an expected target.

Reported experiences were strongly positive. Mean satisfaction for health-related use was 8.91 out of 10, and 77.6% reported improved psychological quality of life. Eleven respondents reported adverse events, most commonly intoxication, dry mouth, altered time perception, and drowsiness or reduced activity. Ten described mild symptoms; one required medical consultation.

Why High Satisfaction Needs Careful Interpretation

Every respondent who rated CBN for insomnia reported some benefit. That sounds compelling until the recruitment method comes into view.

People who had stopped more than 30 days earlier were ineligible. Someone who found a product ineffective or unpleasant and abandoned it could therefore disappear from the sample. Asking current users about satisfaction resembles reviewing a subscription service by interviewing only people who kept renewing.

Their experiences remain meaningful, but they cannot represent everyone who tried the product. The study also lacked a placebo group, relied on retrospective reports, and had a reported response rate of 6.1%.

MyCannabis’s recent examination of more inclusive cannabis trials highlights the broader principle: recruitment influences whose experiences become evidence. For CBN, future research should deliberately follow people who discontinue use, alongside those who remain satisfied.

That would make positive findings more informative. Researchers could establish how often benefits persist, which experiences lead people to stop, and whether different groups need different approaches.

The Important Gap Is Repeated Use

The Japanese averages did not exceed every dose used in modern controlled research. Both were below the single supervised 300 mg dose examined in the recent insomnia trial. The more consequential difference is how exposure occurred.

Laboratory participants underwent screening and received a defined intervention under controlled conditions. Survey respondents selected products and quantities themselves, generally using them at home. A quarter reported existing health conditions.

A successful night also cannot establish what happens after weeks of use. Repeated exposure raises questions about sustained benefit, changing responses, and functioning after waking.

Separate University of Connecticut research on repeated CBN exposure reported signs of physical dependence in mice. Animal findings do not establish dependence rates in people or show that typical consumer products produce the same effects. They do identify a question that human studies should investigate directly.

Similarly, the Japanese survey’s higher preferred-dose figure does not prove tolerance. Researchers collected both answers at one time, and a preferred amount is not a documented consumption history. Establishing tolerance requires observing changes over time under conditions that distinguish it from other explanations.

Better Product Testing Would Strengthen CBN Evidence

Another useful lesson concerns certificates of analysis, commonly called COAs. These laboratory reports can help establish product contents, but their usefulness depends on what was tested and whether it matches the product consumed.

Only six of the 15 included products fully met the study’s original documentation requirement. Those products nevertheless represented the selected product for 91 of 107 respondents. Available reports used different methods, examined different cannabinoid panels, and sometimes concerned batches produced months before the survey.

These details reveal two separate questions. Does a product contain what its label declares? And does that verified formulation produce a useful clinical effect? A laboratory report can help answer the first. It cannot answer the second.

For readers comparing mixed cannabinoid products, MyCannabis’s CBD sleep product buying guide explains why exact ingredients and serving information matter. A CBD sleep product containing CBN is not interchangeable with the CBN-dominant foods examined here.

For future studies, three improvements would make the evidence easier to interpret:

• Test the finished product batch participants actually receive.
• Record consumption, meal timing, benefits, and unwanted effects prospectively.
• Continue follow-up after participants stop using the product.

What the Next CBN Sleep Study Should Measure

The survey suggests a useful next step: a controlled, multiweek study that connects verified formulations with nightly experiences and next-day performance. Researchers should measure both what participants feel and what objective assessments show.

The goal should be to identify an amount that provides meaningful benefit with acceptable tolerability, rather than assuming that a larger number on the label represents progress. A product that helps someone fall asleep but leaves them less alert the next morning presents a different balance from one that improves both sleep and daytime functioning.

Japan’s survey cannot supply that answer. It does provide a clearer picture of consumer expectations and the exposures research needs to address. That is valuable progress: CBN’s future can be shaped by better questions, more representative participation, and evidence that follows people beyond their first experience.

References:

¹ Masataka, Y., Miki, N., Tachibana, S., Nakazawa, R., Akahoshi, Y., Matsumoto, T., & Takumi, I. (2026). Self-reported doses, use patterns, and user-reported effects of high-dose cannabinol (CBN) food products in Japan: A cross-sectional survey (J-NEC2025). Emerging Trends in Drugs, Addictions, and Health. Advance online publication. https://doi.org/10.1016/j.etdah.2026.100287